Results 71 to 80 of about 4,420 (152)

Serum ANGPTL2 and ANGPTL3 as potential biomarkers for diagnosis of non-alcoholic fatty liver disease

Environmental Disease, 2020
Purpose: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease that has a serious effect on worldwide public health. We sought relationships among ANGPTL2, ANGPTL3, and ANGPTL6 with NAFLD metabolic and biochemical parameters, to assess ...
Yan Ma, Yan Wang, Qiang Zhang, Jia-Nan Lang, Long-Yan Yang, Dong Zhao   +5 more
doaj   +1 more source

Cardiovascular Diseases: Exploring Epidemiology, Pathophysiology, Risk Factors, and Medicinal Plant‐Based Therapies: A Narrative Review

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, encompassing coronary artery disease, hypertension, heart failure, and cerebrovascular disorders. The global burden of CVD continues to rise, driven by complex interactions among endothelial dysfunction, oxidative stress, inflammation,
Nawfal Hasan Siam, Umme Halima Mithila, Sadia Alam Tisha, Hridoy Saha, Ayesha Binte Mahbub, Farhan Nizam, Johirul Islam, Noushin Tabasumma, Md. Mazharul Islam Chowdhury   +8 more
wiley   +1 more source

Smart Design: Integrating Artificial Intelligence and Gene Editing for Advanced mRNA Therapeutics

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
The challenges of mRNA therapy and the application of artificial intelligence and gene editing in the field of mRNA drugs. ABSTRACT Artificial intelligence (AI) and gene editing are increasingly being applied to the design and evaluation of mRNA therapeutics.
Haixing Shi, Shengbin Liu, Danni Dai, Shanhui Jiang, Tingchen Tian, Zhenyi Niu, Zhongzheng Xiang, Chaoyu Zou, Fang Liu, Xue Tang, Xin Jiang, Xiangrong Song   +11 more
wiley   +1 more source

Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints

Medicine Bulletin, Volume 2, Issue 4, Page 388-405, September 2026.
ABSTRACT Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention.
Yundong Peng, Rui Li, Huan Li, Jun Zhou, Xuanshi Liu, Guilherme Valente, Tataiana de Campos Melo, Sifan Chen, Lei Gu   +8 more
wiley   +1 more source

Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice

Cell & Bioscience, 2023
Background Gene editing has emerged as an exciting therapeutic development platform for numerous genetic and nongenetic diseases. Targeting lipid-modulating genes such as angiopoietin-related protein 3 (ANGPTL3) with gene editing offers hope for a ...
Yuanbojiao Zuo, Chen Zhang, Yuan Zhou, Haiwen Li, Weidong Xiao, Roland W. Herzog, Jie Xu, Jifeng Zhang, Y. Eugene Chen, Renzhi Han   +9 more
doaj   +1 more source

Conditional eIF2A Deletion Suggests Extra‐Adipose Mechanisms Underlying Metabolic Syndrome in Total‐Body eIF2A Knockout Mice

FASEB BioAdvances, Volume 8, Issue 9, September 2026.
Adipose tissue‐specific deficiency of eIF2A is insufficient to reproduce the metabolic defects observed in total‐body eIF2A knockout mice, suggesting that the systemic metabolic effects observed in these mice may arise from coordinated functions across multiple organs.
Adedeji Isaac Adeloye, Richard Anderson, Anchal Agarwal, Barsanjit Mazumder, Taras Y. Nazarko, Atefeh Bagheri, Archana Prabahar, Peng Jiang, Frank Tedeschi, William C. Merrick, David A. Buchner, Maria Hatzoglou, Roman V. Kondratov, Anton A. Komar   +13 more
wiley   +1 more source

DataSheet_1_A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice.docx

, 2022
IntroductionThe pathogenic mechanisms of diabetic nephropathy (DN) include podocyte injury, inflammatory responses and metabolic disorders. Although the antagonism of Angiopoietin-like protein 3 (ANGPTL3) can alleviate proteinuria symptoms by inhibiting ...
Qianying Lv (12493545), Yuting Zhang (337082), Xiaozhi Hu (3849973), Xue Yang (144876), Dianwen Ju (447665), Tao Wu (16763), Yanyang Nan (5590946), Qianqian Ma (1829734), Lei Han (150108), Hong Xu (71477), Fangyu Liu (92423), Yu Bai (258833), Haidong He (12978554), Kaicheng Zhou (14213603), Zhonglian Cao (2581270), Jia Rao (2266615)   +15 more
core   +1 more source

Regulation of the angiopoietin-like protein 3 gene by LXR

Journal of Lipid Research, 2003
Angiopoietins are members of the vascular endothelial growth factor family. One family member, angiopoietin-like protein 3 (Angpt1111111175), was recently shown to be predominantly expressed in the liver and to play an important role in regulating lipid ...
Rebecca Kaplan, Theresa Zhang, Melba Hernandez, Frank Xiaodong Gan, Samuel D. Wright, M.Gerard Waters, Tian-Quan Cai   +6 more
doaj   +1 more source

A Case Report of Familial Chylomicronemia Syndrome With Infantile Onset: One‐Year Follow‐Up on Lipid Profile and Growth Development

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease caused by a biallelic loss‐of‐function mutation in the lipoprotein lipase (LPL) gene or its cofactors. This case report describes the diagnosis, management, and one‐year follow‐up of an infant with FCS.
Jinyi Liu, Xuanyu Meng, Yi Wu, Guosheng Huang, Shuheng Liang   +4 more
wiley   +1 more source

Role of Angptl3 in the Hypothalamic Control of Energy Metabolism

, 2015
Angptl3 is a secretory glycoprotein which belongs to the angiopoietin-like family. Angiopoietin-like peptide 3 (Angptl3) critically regulates the clearance of circulating lipids by inhibiting lipoprotein lipase (LPL).
김현경
core